Impact of Treatment on the Quality of Life in Patients with Critical Limb Ischaemia

Hernández-Osma, E.; Cairols, Marc; Barjau, E.; Riera, Santiago

doi:10.1053/ejvs.2002.1644

Cited by 32 publications

(17 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[17][18][19][20][21] No significant differences between the two trial arms emerged across a range of generic and disease-specific HRQOL measures. 22 Although patients had a very low HRQOL before treatment, BSX and BAP both had very similar effects on short-term gains in HRQOL that were sustained for at least 3 years after randomization.…”

Section: Discussionmentioning

confidence: 99%

Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: Health-related quality of life outcomes, resource utilization, and cost-effectiveness analysis

Forbes

Adam

Bell

et al. 2010

Journal of Vascular Surgery

117

101

View full text Add to dashboard Cite

Adopting a BSX-first strategy for patients with severe limb ischemia does result in a modest increase in hospital costs, with a small positive but insignificant gain in disease-specific and generic HRQOL. However, the real-world choice between BSX-first and BAP-first revascularization strategies for severe limb ischemia due to infrainguinal disease cannot depend on costs alone and will require a more comprehensive consideration of individual patient preferences conditioned by expectations of survival and other health outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: Health-related quality of life outcomes, resource utilization, and cost-effectiveness analysis

Forbes

Adam

Bell

et al. 2010

Journal of Vascular Surgery

117

101

View full text Add to dashboard Cite

show abstract

“…15 In light of its high sensitivity and specificity, 16,17 correlation with disease severity, 18 ability to predict future cardiovascular events, 19 ease of performance, and low cost, the ABI has long been considered the gold standard for the diagnosis of PAD. Although not specifically validated as a screening tool in patients undergoing nontraumatic amputation, given the cost, morbidity, and decrement in quality of life associated with lower extremity amputation, [20][21][22] the threshold for measurement of the ABI should be low. For these reasons, The optimal amount of preamputation arterial testing has yet to be defined based on test characteristics, outcomes studies, and cost-effectiveness studies.…”

Section: What the Study Addsmentioning

confidence: 99%

Peripheral Arterial Testing Before Lower Extremity Amputation Among Medicare Beneficiaries, 2000 to 2010

Vemulapalli

Greiner

Jones

et al. 2014

Circ: Cardiovascular Quality and Outcomes

View full text Add to dashboard Cite

show abstract

“…[10][11][12][13][14][15][16][17][18][19][20][21][22][23] We used the NBS method for the SF-36. The norm-based transformation of the scores to general population means allows comparison of the physical and mental components of the health of patients with similar and other underlying conditions.…”

Section: Discussionmentioning

confidence: 99%

Quality of life in patients with no-option critical limb ischemia underlines the need for new effective treatment

Sprengers

Teraa

Moll

et al. 2010

Journal of Vascular Surgery

View full text Add to dashboard Cite

on behalf of the JUVENTAS and SMART study groups, Utrecht and Bilthoven, The Netherlands Objective: To provide a solid baseline reference for quality of life (QoL) in patients with no-option critical limb ischemia (CLI). CLI is associated with surgery, endovascular interventions, hospitalization, and a poor prognosis. An increasing number of clinical trials are, therefore, investigating new treatment strategies (eg, therapeutic neovascularization) in patients with CLI. QoL serves as an important secondary endpoint in many of these trials, but solid reference QoL data for patients with no-option CLI are lacking. Methods: The Medical Outcomes Study Short Form 36 (SF-36) and the EuroQol-5D (EQ-5D) questionnaires were used to obtain baseline QoL scores from 47 patients with no-option CLI participating in a therapeutic neovascularization trial. To allow for easy comparability, a norm-based scoring (NBS) method was used to report the results of the SF-36. Scores of patients with CLI were furthermore compared with scores of patients with milder forms of peripheral arterial disease (PAD) and with patients with cardiovascular risk factors only. Determinants of QoL in patients with PAD were identified using multiple linear regression methods. Results: Patients with no-option CLI reported QoL scores below the general population mean on every health dimensionof the SF-36. Physical functioning, role physical functioning, and bodily pain were affected most intensively. These poor physical QoL scores were further underlined when compared with other patients with milder forms of PAD or patients with cardiovascular risk factors only. Patients with CLI scored poorly on the pain/discomfort and the usual activities domain of the EQ-5D. Diabetes, female gender, body mass index, and the ankle-brachial index at rest were significant determinants of the QoL in PAD on multivariate analysis. Conclusion: The QoL data of patients with no-option CLI using NBS methods for the SF-36 provide a baseline reference for ongoing clinical trials on new treatment strategies. Our data stress the need for new revascularization therapies in patients with no-option CLI. ( J Vasc Surg 2010;52:843-9.)

show abstract

Impact of Treatment on the Quality of Life in Patients with Critical Limb Ischaemia

Abstract: our results suggest that changes in dimensions of QOL obtained by limb revascularisation do not differ from those of other therapeutic approaches.

Cited by 32 publications

References 15 publications

Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: Health-related quality of life outcomes, resource utilization, and cost-effectiveness analysis

Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: Health-related quality of life outcomes, resource utilization, and cost-effectiveness analysis

Peripheral Arterial Testing Before Lower Extremity Amputation Among Medicare Beneficiaries, 2000 to 2010

Quality of life in patients with no-option critical limb ischemia underlines the need for new effective treatment

Contact Info

Product

Resources

About